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Although the ideal treatment route for 
management of patients with ST-segment 
elevation myocardial infarction (STEMI) is rapid 
diagnosis and direct transfer to the catheterization 
unit and undergoing primary angioplasty, using 
thrombolytic still has its place in cases that the 
equipment are not available or there is not enough 
time for performing angioplasty (1, 2). Of course 
these drugs are associated with specific side effects 
such as probability of gastrointestinal (GI) and 
cerebral bleeding, allergic reactions and etc. (2). 
Therefore, finding drugs with fewer side effects 
and limitations for use has always been interesting 
in this regard. The drug which has been used all 
around the world since 1970 and is also 
traditionally used in Iran for managing patients 
with STEMI is streptokinase. This drug is a protein 
extracted from beta hemolytic streptococci, which 
combines with plasminogen and facilitates 
transformation of plasminogen to plasmin. 
However, recently fibrin specific drugs or 
recombinant tissue plasminogen activators (rtPA) 
such as alteplase, urokinase, tenecteplase, 
reteplase and etc. have become available to 
emergency medicine physicians and cardiologists 
(3). Having longer half-lives, fewer side effects, and 
easier method of use, these drugs have opened a 
new door for physicians regarding use of 
thrombolytic drugs in treatment of STEMI and 
brain stroke. Studies regarding comparison of 
safety and effectiveness of these drugs are ongoing. 
In a systematic review and meta-analysis, Tourani 
et al. showed that the safety and effectiveness of 
streptokinase and tenecteplase were in the same 
level (4).  
Reteplase is an rtPA peptide, which converts 
endogenous plasminogen to plasmin. Plasmin 
causes destruction of the fibrin present in the clot 
and the clot disappears. In a prospective case-
control study in Amiralmomenin Hospital, Tehran, 
Iran, we divided 152 patients with STEMI and the 
mean age of 56.41 ± 10.40 (27 – 85) years who 
were candidates for receiving thrombolytic 
therapy into 2 groups receiving either 
streptokinase (from CSL Behring GmbH Co, 
Germany) or reteplase (from Reliance Life Sciences 
Co, India) (83.6% male). Then we compared 
outcomes such as GI bleeding, mortality, 
hypotension, arrhythmia, and etc. between the 2 
groups. The 2 groups were in a similar condition 
regarding sex (p = 0.331) and age distribution (p = 
0.393), blood pressure on admission (p = 0.378), 
and the rate of positive troponin on admission (p = 
0.113). Overall, 61 (40.1%) patients showed at 
least one of the outcomes that we studied (13 cases 
in the streptokinase group and 48 cases in the 
reteplase group; p < 0.0001). In this study, all 20 
cases of GI bleeding observed following 
thrombolytic prescription were in the reteplase 
group. Additionally, out of the 19 cases of death 
observed, 14 were in reteplase group and 5 had 
received streptokinase. One case of arrhythmia and 
2 cases of hypotension were seen in streptokinase 
group. Based on the findings of this study, it seems 
that despite factors such as longer serum half-life 
and ease of use, the rate of side effects of this drug 
should be carefully considered before use. Based 
on some existing studies, it seems that in the most 
optimistic scenario, these 2 groups have similar 
side effects and effectiveness (4, 5).  
For a more accurate assessment at least regarding 
the Iranian race, more accurate studies with larger 
sample size are required. This topic might have 
received less attention in developed countries as 
considering availability of equipment in those 
countries, treatment protocols are mostly based on 
angioplasty and not using thrombolytic drugs 
there. This subject becomes more important when 
we are aware of the higher treatment costs of these 
new drugs for patients since insurance does not 
cover them. Performing cost/benefit studies and 
evaluating the safety of treatment are suggested for 
future studies. 
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